Mitemcinal (GM-611), an erythromycin-derived prokinetic agent, was developed by Chuga as an agonist of the motilin receptor. Mitemcinal acts by a novel mechanism whereby it stimulates and promotes peristalsis in the stomach and other segments of the gastrointestinal tract. This drug was studied as a potential treatment for gastric motility disorder, as well as reflux esophagitis, non-ulcer dyspepsia, and diabetic gastroparesis. Mitemcinal was involved in phase II clinical trials in Patients with diabetic gastroparesis. Although gastroparetic symptoms improved with both mitemcinal and placebo, the prominent placebo effect was not statistically exceeded by mitemcinal. That is why the development of this drug has stalled. In addition, mitemcinal has been studied in phase II for the treatment of irritable bowel syndrome, but this study was also discontinued.

Mezilamine is a dopamine antagonist, it blocks presynaptic but stimulates postsynaptic alpha-adrenoceptors. Potential antipsychotic drug.

Methastyridone (MK-202), a centrally acting stimulant, was studied with chronic anergic schizophrenics. Information about the current use of this compound is not available.

Furethidine, a pethidine analog was studied as an analgesic agent. This compound is not currently used in medicine and is listed in schedules of the single convention on narcotic drugs of 1961 as amended by the 1972 protocol.

IQUINDAMINE is an antitussive agent.

Mexafylline, a theophylline derivative, is a bronchodilator that has never been marketed.

Cefetrizole is aminocephalosporanic acid derivative with broad antibacterial activity against penicillin-resistant strains patented by Spanish pharmaceutical company Ferrer Internacional S. A.

Mengylate is an antitussive and local anesthetic.